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Endocrine disruptors are hormone mimics that modify hormonal action in humans and animals.
It is thoughtthatsome endocrine disruptorsmodifyestrogen andandrogen action inhumansand
animals by suppressing aromatase activity. Aromatase cytochrome P450 is the key enzyme that
converts C19 androgens to aromatic C18 estrogenic steroids. We have developed a novel aro-
matase inhibitor screening method that allows us to identify antiaromatase activity ofvarious
environmental chemicals. The screen was developed by coexpressing the human aromatase and
the mouse androenrceptor in yeast ceals, which carry the androgen-responsive ,B-galactosidase
reporter plasmid. Functional expression ofaromatase in yast has been donstrated using the
PHI-water release assaywith intact cells aswell aswithyeast microsomes. The aromatase activity
could be blocked by known aromatase inhibitors such as aminogluhimide (AG). Yeast-pro-
duced androgenreceptorswereabletotransactivate ayeastbaalpromoterlinkedtoanandrogen-
responsive element in response to androgens. The resultant triple yea transformant responde
to the treatment oftestosterone, androstenedione, or 5a-dihydrotesosterone (5a-DHT). In the
absence of the aromatase inhibitor AG, transcriptional activation was observed only for the
nonaromatizable androgen 5a-DHT. However, the two aromatizable androgens (testosterone
and androstenedione) induced the reporteractivity in the presence ofAG. Using this yeast-based.
assay, weconfirmed that two &favones, chrysin anda-n ahtholflone, are inhibitors ofaromatase.
Thus, thisyeast system allows us to develop ahigh-throughput screening method, without using
radioactiv substrate, to identify aromatase inhibitors as well as new ligands (nonaromatizable
androgen mimics) for theandrogenreceptors. Inaddition, this mehodalsoallows us to
distnguish nonandrogenic aromatase inhibitors from inhibitors with androgenic activity. This
yeast screening methodwill be useful to screen environmental cemicals for their antiaromatase
activity and for their interaction with androgen receptor. Key words: androgen receptor, aro-
matase, cytochrome P450, endocrinedisruptors,yeastscreeningmethod. EnvironHeal Perspect
107:855-860 (1999). [Online 28 September 19991
http://e,Jpnetl.nckbs.nibgolv/docs/1999/107p855-860maklabstract.hml
The conversion of androgens to estrogens is
catalyzed by the enzyme aromatase, which
belongs to the cytochrome P450 superfamily.
Aromatase plays an important role in the
expression ofsecondary sexual characteristics,
maintenance ofpregnancy, and brain sex dif-
ferentiation (1). Furthermore, the enzyme
has received considerable attention in breast
cancer development because high expression
of the enzyme activity has been associated
with a significant number of breast tumors
(2-4). Thus, aromatase inhibitors are used
as therapeutic agents for the treatment of
estrogen-dependent breast cancer by inhibi-
tion of estrogen production in addition to
antiestrogen treatment.
Aromatase inhibitors can be separated
into two classes based on their mechanisms of
action. Aromatase inhibitors such as 4-
hydroxyandrostenedione (4-OHA) and 1,4,6-
androstatrien-3,17-dione (ATD) are steroidal
substrate analogs, which inhibit the enzyme
activity bycompeting for the active site ofthe
enzyme (5). The other class of inhibitors is
nonsteroidal inhibitors such as aminog-
lutethimide (AG), which interact with the
heme prosthetic group ofaromatase (6).
Endocrine disruptors are hormone mim-
ics that modify hormonal action in humans
and animals (7-9). These compounds indude
chemicals isolated from plants (such as phy-
toestrogens) and man-made chemicals (such
as dioxins and polychlorinated biphenyls).
There is increasing concern about how many
such chemicals are present in our environ-
ment. There is a need for high throughput
approaches to examine various environmental
chemicals. Endocrine disruptors bind to the
estrogen receptor or androgen receptor and
induce many components of estrogen or
androgen action (10-12). We feel that it is
also possible that some of these compounds
may act in an indirect fashion by inhibiting
aromatase activity, resulting in a decrease in
the level of estrogens or an increase in the
level of androgens in cells. Research from
other laboratories as well as our own has
demonstrated that phytoestrogens such as
flavones are competitive inhibitors of aro-
matase (13-15). Some flavones can inhibit
aromatase with A? values similar to that of
AG, an approved drug for treating breast can-
cer. It is possible that there are additional
environmental chemicals that can suppress
aromatase activity by competing for the bind-
ing ofthe androgen substrates or by interact-
ingwith thehemegroup ofaromatase.
The conventional method for aromatase
inhibitor screening uses an in vitro enzyme
assay with human placental microsomes as
sources of the enzyme. However, the aro-
matase assay in such preparations depends
on several components including short incu-
bation time, the stability of NADPH-
cytochrome P450 reductase and aromatase
in such preparations. Furthermore, the assay
procedure is tedious and it would not be
easy to adapt this assay for high-throughput
screening. Although certain intact cells
expressing aromatase, including human aro-
matase transfected mammalian cell lines
(16), provide an ideal in vivo model for aro-
matase inhibitor screening, the cost ofmam-
malian cell culture is a concern. In addition,
these expression systems require an enzyme
assay that uses radioactive substrates, which
is a limiting factor for high-throughput
screening. To circumvent these problems,
we developed a novel method, which does
not involve a radioactive assay, by coexpress-
ing the human aromatase enzyme and the
mouse androgen receptor in yeast cells carry-
ing the androgen-responsive reporter plas-
mid. We also provide evidence that this
high-throughput screening method can dif-
ferentiate aromatase inhibitors with or with-
out androgenic activity.
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Materials and Methods
Chemicals andbuffers. Restriction enzymes,
T4 polynucleotide kinase, and T4 DNA lig-
ase were purchased from New England
Biolab (Beverly, MA). Taq polymerase was
from Perkin-Elmer Cetus (Norwalk, CT).
1,2-[3H]-Androstenedione (55 Ci/mmol)
and 1,2,5,6,7-[3H]-5a-dihydrotestosterone
(5a-DHT) (120 Ci/mmol) were from
DuPont-New England Nuclear (Boston,
MA). AG, 4-OHA, and o-nitrophenyl-3-D-
galactopyranoside were obtained from Sigma
(St. Louis, MO). Testosterone, androstene-
dione, 1,4,6-androstatrien-3,17-dione and
other steroids were obtained from Steraloids
(Newport, RI), yeast nitrogen base and dex-
trose from Difco (Detroit, MI), Glassperlen
from B/Braun Melsungen AG (Melsungen,
Germany), and 5-bromo-4-chloro-3-indoyl-
P-D-galactoside (x-gal) from Bio-Rad
(Hercules, CA).
Transcrption bufferfor 3-galactosidse
assay. We used sodium phosphate (0.12 M
dibasic), 0.04 M sodium phosphate
(monobasic), 10 mM potassium chloride, 1
M magnesium sulfate, and 0.27% 2-mercap-
toethanol, pH 7.0 (room temperature), for
the transcription buffer.
Yeast strains. We used the Saccharomyces
cerevisiae strain BJ2168 (Mat a, a prcl-407
prbl-1122pep4-3 leu2 trpl ura3-52) (17).
LEU2 CUPl UBI | Mouse androgen receptor CYC1
URA3 GRE/PRE Iac-
CYCl lac-Z i l
TRP1 TDH3 UBI Aromatase CYCl
Figure 1. (A) Androgen receptor expression plas-
mid (YEpARc). Abbreviations: CUP1, copper-
inducible promoter; CYCl, iso-i-cytochrome c
gene; GRE/PRE, glucorticoid/progesterone
response element; LEU2, leucine selectable mark-
er; TDH3, triose phosphate dehydrogenase; TRP1,
tryptophan selectable marker; UBI, ubiquitin;
URA3, uraxil selectable marker. The mouse
androgen receptor cDNA was inserted into the
yeast expression plasmid to produce a UBI-fusion
receptor under the control ofthe CUP1. (B) Yeast
reporter plasmid (YEpA). The yeast upstream reg-
ulatory elements of the CYCl promoter were
replaced by an oligonucleotide containing two
copies of an androgen-responsive element
(GRE/PRE) inserted into the Xhol site upstream of
the CYCl promoter, which is fused to the lac-Z
gene of Escherichia coli. (C) Aromatase expres-
sion plasmid (YEpARO). The human aromatase
cDNAwas inserted intothe yeast expression vec-
tor to produce an UBI-fusion protein under the
control of the TDH3 promoter. All three vectors
are 2-micron plasmids.
Expression ofthe human aromatase was under
the control of a constitutive yeast promoter,
triosephosphate dehydrogenase (TDH3);
expression of the mouse androgen receptor
was under the control ofa regulated yeast pro-
moter, metallothionein promoter (CUP1) as
described previously (18). Growth and trans-
formation of yeast cells were performed
according to standard procedures (19).
Construction ofyeast expression vector
for the mouse androgen receptor. A cassette
that contained the metallothionein promot-
er (CUP1)-ubiquitin gene-linker containing
unique Eagi and BssHII sites followed by
the iso-1-cytochrome C (CYCI) terminator
was inserted into the BamHI and the SphI
sites (multiple cloning sites) of the yeast
vector (YEp351). The mouse androgen
receptor cDNA was excised from the previ-
ously described yeast expression vector
(YEpmAR) (20) after complete digestions
with Eag and BssHII and was subsequently
ligated to YEp351. The resultant androgen
receptor expression vector (YEpARc)
(Figure IA) was used to transform the yeast
strain, BJ2168, using lithium acetate proto-
col (19). Transformants were selected by
leucine auxotrophy.
Construction ofandrogen-responsive
reporterplasmid. The reporter plasmid
(YEpA) was used to study the transcriptional
activation of the mouse androgen receptors
produced in yeast cells (20). Briefly, an
oligonucleotide containing two copies ofthe
glucocorticoid/progesterone response ele-
ment (GRE/PRE) from the tyrosine amino-
transferase gene (21) was inserted into the
unique XboI site of the yeast reporter plas-
mid, pCl, as described previously (18,20).
The resulting reporter plasmid (YEpA)
(Figure 1B) contains an androgen response
element (GRE/PRE) upstream ofthe CYCI
promoter that is fused to the lac-Zgene of
Escherichia coli. These plasmids were used to
transform yeast cells expressing the mouse
androgen receptor and the final transfor-
mants (YEpARc/YEpA) were selected by
leucine and uracil auxotrophy.
Construction ofyeast expression vector
for human aromatase. Two unique restric-
tion sites were engineered at the 5' and the
3' ends of the human placental aromatase
coding sequence (16,22) for insertion into
theyeast expression vector (YEpV5) described
previously (18). This was achieved by PCR-
mediated mutagenesis.
The two primers used to amplify the aro-
matase gene (1.5 kb) were 5'-ACTTCACG-
GCCGATGGTTTTGGAAATGCT-
GAACCA-3' (forward) and 5'-ACTTCA-
CACACAGTGCTAGTGTTCCAGACAC-
CTGTC-3' (reverse).
The resultant aromatase cDNA con-
tained an Eagl site in front ofthe start codon
and a DraIll site right after the stop codon.
To produce an in-frame ubiquitin-fusion
receptor under the control oftheyeastTDG3
promoter, an oligonucleotide containing the
last six amino acids ofthe ubiquitin gene fol-
lowedby an Eagl and a DraIII site was insert-
ed into the AflII-Kpn sites of the yeast
expression vector, YEpV5. After complete
digestions with Eagl and DraIII, the aro-
matase cDNA was inserted into the yeast
expression vector (YEpV5). The resultant aro-
matase expression vector (YEpARO) (Figure
IC) was used to transform BJ2168 yeast
strain carrying the androgen receptor expres-
sion construct and the androgen-responsive
reporter plasmid (YEpARc/YEpA). The final
triple transformant yeast strain (YEpARc/
YEpARO/YEpA) was selected by leucine,
uracil, andtryptophan auxotrophy.
Aromatase assay. The aromatase activity
was measured by [3H]-water assay (23)
directly on yeast cultures. The [3H]-water
release assay for human aromatase expressed
in mammalian cells and yeast was validated
in our laboratory by a product isolation assay
(16,22). [3H]-Androstenedione at a final
concentration of46 nM was added to 1 mL
transformed yeast strain (YEpARc/YEpARO/
YEpA) when cell density reached the late log
phase. After 1-hr incubation at 30°C, the
reaction was stopped by addition of 200 1sL
10% (weight/volume) trichloracetic acid and
100 pL dextran-coated charcoal (2% norit A
and 0.2% dextran in water). After 10 min
incubation, the suspension was centrifuged
and the supernatant was again treated with
dextran-coated charcoal. After centrifugation,
the supernatant was filtered through a small
column fitted with glass wool and the tritiat-
ed water content was determined by scintilla-
tion counting. For the in vitro enzyme assay,
microsomes were prepared from yeast cells as
follows: Yeast cells were washed with enzyme
buffer (50 mM Tris-HCI and 1 mM EDTA,
pH 7.0) and disrupted with glass beads. This
and subsequent procedures were performed
at 40C. The cell suspension was centrifuged
at 1,000 x gfor 10 min, and the supernatant
was centrifuged at 10,000 x g for 30 min.
The resulting supernatant was further cen-
trifuged at 100,000 x gfor 30 min to obtain
the yeast microsomal pellet. Yeast micro-
somes (20 pL) were added to 180 jL enzyme
buffer containing NADPH (0.2 mg/mL) and
[3H]-androstenedione at concentration as
indicated. After 20 min incubation at 37°C,
the reaction was stopped by the addition of
20 pL 50% trichloroacetic acid. The rest of
the procedure was identical to that described
for the yeastculture assay.
Preparation ofyeast extracts and recep-
tor-binding assays. Yeast extracts were pre-
pared for androgen receptor-binding assay as
described previously (18,20).
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Transcription assays. The triple transfor-
mantyeaststrainwasgrown inenriched medi-
um (without tryptophan, uracil, and leucine)
containing 20 nM androstenedione in the
presence or absence ofaromatase inhibitors.
When cell density reached the late log phase,
cellswere harvested bycentrifuigation andsub-
sequently disrupted by vortexing with glass
beads. Cell suspension was centrifuged at
10,000 x gfor 10 min and the supernatant
(yeast extract) was assayed for [3-galactosidase
activityasdescribed previously(18,20).
Plateassayforhigh-throughputscreening.
An overnight cultureyeaststrain (YEpmARc/
YEpARONYEpA2) (5%) was inoculated into
dextrose-agar medium maintained at 50°C.
After the addition ofvitamins, amino acids,
x-gal, and 20 nM androstenedione, the final
culture was poured onto a 15-cm petri plate
and allowed to cool at room temperature.
Discs containing different aromatase
inhibitors were placed on top ofthe agar and
the plate was incubated for 2 days at 300C.
As acontrol, another culture plate containing
the same constituents without 20 nM
androstenedione was also set up simultane-
ously to detect the androgenic activity ofaro-
matase inhibitors.
Results and Discussion
Concept ofcoexpressing androgen receptor
and aromatase inyeast as a novelscreening
methodforantiaromataseactivity. In the pre-
sent study, we developed a screening method
to identify aromatase inhibitors without using
an enzyme assay with radioactive substrates.
This concept was achieved by coexpressing
androgen receptorandaromatase inyeast cells
carrying the androgen-responsive reporter
plasmid. Ifthe triple transformant yeast cells
carrying the three plasmids as described in
Figure 1 are incubated with an aromatizable
androgen (testosterone or androstenedione),
the androgen diffuses into the cell, where it
will either bind to theyeast-produced andro-
gen receptor orwill be converted to estrogen
by aromatase produced in yeast. If the con-
ditions (concentrations and choice of sub-
strates) favor the enzymatic reactions, most
ofthe androgen will be converted into estro-
gen but not bind to the androgen receptor
and therefore cannot transactivate the yeast
basal promoter linked to the androgen-
responsive element (GRE/PRE). The end
result of this androgen metabolism within
the yeast cells is the inhibition or reduction
of reporter enzyme 3-galactosidase induc-
tion. However, androgen-dependent tran-
scriptional activation will be apparent as
reflected by the reporter enzyme induction if
an aromatase inhibitor is included in the
yeast medium. As a first step toward the
development of this novel screen, the two
expression systems for androgen receptor
and aromatase in yeast must be characterized
andvalidated separately.
Androgen-dependent transcriptional
activation in yeast. We have previously
shown that many of the steroid/retinoid
receptor superfamily can function as ligand-
activated transcription factors in yeast cells
(18,20,24,25). In this study, a newyeast vec-
tor carrying the CUPI promoter and a
LEU2 gene was constructed to express the
mouse androgen receptor. To confirm recep-
tor expression, yeast extracts were prepared
from the yeast strain carrying this expression
vector (YEpARc) under copper induction
and analyzed for receptor-binding activities.
Scatchard analysis indicated that the yeast-
produced mouse androgen receptor binds to
androgen with high affinity with a Kd value
of0.96 nM and a maximum binding capaci-
ty of 135 fmol/mg (Figure 2). The binding
specificity of these receptors was also exam-
ined by labeling the extracts with 10 nM
[3H]-5a-DHT in the presence or absence of
1-, 10- and 100-fold molar excess ofradioin-
ert competitors (Figure 3). Yeast-produced
androgen receptors exhibit steroid-binding
specificity characteristics of the authentic
mammalian androgen receptor. The func-
tional expression ofthe androgen receptor in
yeast was further confirmed by transforming
the yeast strain (YEpARc) with a reporter
plasmidcontaining two copies ofaGRE/PRE
of the glucocorticoid responsive tyrosine
aminotransferase gene upstream of the yeast
promoter, CYCI, which is fused to the lac-Z
gene ofE. coli. The resultingdouble transfor-
mant yeast strain (YEpARcIYEpA) was ana-
lyzed for ligand-dependent transcriptional
activation. In the presence of 10 pM cupric
sulfate, the three androgens (androstene-
dione, testosterone, or 5a-DHT) were able
to induce the P-galactosidase activity in the
absence or presence ofAG (1 mM) (Figure
4). These results indicate that aromatase
inhibitors such as AG do not interfere with
the binding of androgens to the expressed
androgen receptor. We also observed that the
reporter enzyme could be induced (3- to 4-
fold) by high concentrations ofandrogen (.
1 pM) in yeast cells in the absence ofcopper,
indicating that the CUP promoter is slightly
leaky (data notshown).
Expression ofaromatase in yeast. Baker's
yeast (S. cerevisiae) is an ideal host for
expressing mammalian cytochrome P450s,
including aromatase (22). In the present
study, we used the previously described
ubiquitin-fusion technology (18,20,21) to
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Figure 2. Saturation analysis ofyeast-produced mouse androgen receptor. Abbreviations: 5a-DHT, 5o
drotestosterone; NS, nonspecific binding; S, specific binding; T, total binding. (A) Yeast extracts pre
from a yeaststrain carrying the androgen receptorexpression plasmid (YEpARc) under induced condr
copper) were incubated with increasing concentrations ofPHI-5ac-dihydrotestosterone inthe absence
presence (NS) of a 100-fold molar excess of radioinert 5a-DHT. S was determined by NS - T. (B) Scal
plotanalysis ofthe data from (A).Two experiments gave similarapparentKd values. Kd = 9.6 x 10-10 M.
am Figure 3. Steroid binding specificity of yeast-
produced mouseandrogen receptor. Abbreviations:
_ 5a-DHT, 5a-dihydrotestosterone; DES, diethylstil-
bestrol; T, testosterone; R1881, methyltrienolone;
E CA, cyproterone acetate; E2, 17,B-estradiol; P4,
30 progesterone; F, flutamide; TAM, tamoxifen.
Aliquots ofyeast extracts containing the recombi-
nant mouse androgen receptor were incubated
c-dihy- with 10 nM 13HI-5a-DHT in the absence (100%
,pared control) or presence of a 1-, 10-, or 100-fold molar
tion (+ excess of radioinert 5a-DHT, T, R1881, CA, E2, P4,
(T) or F, TAM, or DES. Bound [3HI-5Sx-DHT was deter-
tchard mined as described in "Materials and Methods."
Values representthe average oftwo experiments.
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express human aromatase functionally in
yeast cells. Because a unique EagI restriction
site was created in front ofthe start codon of
the aromatase gene during the construction
ofthe ubiquitin-fusion protein, the resulting
recombinant aromatase contains two extra
amino acids (arginine and proline) in front
of the methioinine after the ubiquitin (76
amino acids) has been deaved offby the host
enzyme. To test whether this recombinant
aromatase produced by yeast is functional,
aromatase enzyme activity was determined in
yeast microsomes by the [3H]-water release
assay. A double-reciprocal plot of the
enzyme activity revealed an apparent
Michaelis-Menton constant (Ki) of 50 nM
and a maximum velocity of 6 pmol [3H]-
water release/min/mg microsomal protein
(Figure 5). The Km value is similar to those
reported for aromatase in human placental
microsomes, but the Vma. is lower than
those reported previously in placental micro-
somes (26). Paradoxically, this lower level of
enzyme expression in yeast actually enhances
the sensitivity ofthe screen because reporter
enzyme induction can be detected in the
presence of lower concentrations of aro-
matase inhibitor.
The three aromatase inhibitors (4-OHA,
ATD, and AG) were tested on the yeast
strain carrying the aromatase expression con-
struct (YEpARO). As shown in Figure 6, 4-
OHA and ATD were effective inhibitors,
with a median inhibitory concentration of
0.1 pM. These two inhibitors were able to
inhibit 90% ofthe aromatase enzyme activi-
ty at a concentration of 1 pM, whereas the
nonsteroidal inhibitorAG required 1 mM to
achieve a similar inhibitory effect. Relatively
high concentrations of aromatase inhibitors
were needed to suppress aromatase in yeast.
This observation is likely because ofthe poor
ability of the compounds to diffuse into the
yeast cells. We are evaluating approaches to
increase the sensitivity ofthe assay. Although
aromatase inhibitor screening using the yeast
strain expressing the human aromatase would
be a good approach because of rapid cell
growth and the stability of the expression
plasmid attributed bythe auxotrophic marker,
this screening method involves an enzyme
assay, which will require a large quantity of
radioactive substrates when high-volume
screening is desired. An ideal aromatase
inhibitor screening should handle a large
number ofsamples with good selectivity, sen-
sitivity, and capacity. To accomplish this goal,
we coexpressed the androgen receptor and the
aromatase enzyme in yeast cells carrying the
androgen-responsive reporterplasmid.
Coexpressing aromatase and androgen
receptor inyeast. The yeast strain expressing
the aromatase enzyme was cotransformed
with the androgen receptor expression vector
and the androgen-responsive reporter plas-
mid. The three androgens (testosterone,
androstenedione, and 5a-diydrotestos-
terone) were tested for reporter enzyme
induction in the triple transfromant yeast
strain (YEpARc/YEpAROIYEpA). As shown
in Figure 7, the aromatizable androgens
androstenedione and testosterone were not
able to induce the reporter enzyme in the
absence of the aromatase inhibitor, AG.
However, ligand-dependent transcriptional
activation was apparent in the presence of
AG (1 mM). Addition ofAG alone in the
yeast culture did not induce reporter enzyme
activity. In contrast to aromatizable andro-
gens, the nonaromatizable androgen, 5a-
DHT, induced the reporter gene efficiently
in the presence or absence of AG. Thus,
these data clearly support our concept of
coexpressing the androgen receptor and the
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aromatase enzyme in yeast as a novel aro-
matase inhibitor screen.
To develop a high-throughput screening
assay, the yeast strain carrying the threeplas-
mids (YEpARc, YEpARO, and YEpA) were
inoculated on agar plates, which contained
the chromogenic substrate, x-gal, and
androstenedione (20 nM). Discs containing
10 pg of the three aromatase inhibitors, 4-
OHA, ATD, andAG, wereplaced on top of
the agar (Figure 8A). After 48 hr incubation
at 300C, blue halo formations as a result of
3-galactosidase induction were detected sur-
rounding these inhibitors. To distinguish
androgenic from nonandrogenic aromatase
inhibitors, the three inhibitors were also test-
ed with the same yeast strain in the absence
of androstenedione (Figure 8B). Both 4-
OHA and ATD exhibited transcriptional
activation as reflected by the formation of
low
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Figure 4. Androgen-dependent transcriptional
activation in yeast. Abbreviations: Ad, androste-
nedione; AG, aminoglutethimide; C, control; DHT,
5a-dihydrotestosterone; T, testosterone. The
three androgens (Ad, T, and DHT) were incubated
with the yeast strain carrying the mouse andro-
gen receptor expression plasmid and the reporter
plasmid (YEpARc/YEpA) under induced conditions
in the absence or presence of the aromatase
inhibitor, AG (1 mM). Reporter enzyme (j3-galac-
tosidase) activities were measured in yeast
extracts. Values represent the average of two to
three experiments. Yeast culture without andro-
gen incubation was used as the control.
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Figure 5. Enzyme kinetic analysis of yeast-pro-
duced aromatase. Km = 50 nm. Vmax = 6 pmol [3H]-
H20/min/mg protein. The aromatase enzyme
activity was determined in microsomes prepared
from the yeast strain carrying the aromatase
expression plasmid (YEpARO) using the tritiated
water assay described in 'Materials and
Methods."
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Figure 6. Inhibition of aromatase activity in yeast
cells. Abbreviations: AG, aminoglutethimide; ATD,
1,4,6-androstatrien-3,17-dione; 4-OHA,4-hydroxyan-
drostenedione. Yeast cells carrying the aromatase
expression plasmid (YEpARO) were incubated with
the substrate, [3H]-androstenedione (46 nM) in the
absence or presence of an increasing concentra-
tion of the aromatase inhibitors, 4-OHA, ATD, and
AG.Assay conditions were described in "Materials
and Methods." Enzyme activity in the absence of
inhibitors wastaken as 100%.
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Figure 7. The three androgens (Ad, T, and DHT)
were tested in thetriple transformant yeast strain
(YEpARc/YEpARO/YEpA) under induced condi-
tions in the absence or presence of the aro-
matase inhibitor, AG (1 mM), as described in
Figure 5. Abbreviations: Ad, androstenedione;AG,
aminoglutethimide; C, control; 5a-DHT, 5a-dihy-
drotestosterone; T, testosterone. Values repre-
sentthe average oftwo tothree experiments.
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blue halos surrounding the discs, whereas
the nonsteroidal inhibitor, AG, was inactive
on this control plate. The observation indi-
cates that 4-OHA and ATD are androgen
mimics. The detection of an androgenic
activity ofthese inhibitors may be due to the
fact that a rather high amount of com-
pounds was used. These compounds report-
edly have weak androgenic activity (27-30).
The binding affinity of 4-OHA to the
androgen receptor is 0.1% that of mibo-
lerone (30). Using this yeast screening
method, we confirmed our previous report
(13) that two endocrine disruptors, chrysin
and a-naphtholflavone, are aromatase
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Figure 8. Coexpression of androgen receptor and
aromatase in yeast as a high throughput screen
to identify aromatase inhibitors. Abbreviations:
AG, aminoglutethimide; ATD 14- 4 androstatrien-
3,17-dione; 4-OHA, 4-hydroxyandrostenedione. (A)
The yeast strain (YEpARc/YlEpARO/YEpA) was
inoculated in medium containing 5-bromo-4-
chloro-3-indoyI-p3-o-galactoside and 20 nM
androstenedione as described in `Materials and
Methods." Discs containing 10 pg ofthe aromatase
inhibitors 4-OHA, ATO, orAG were placed on top of
the agar plate, which was then incubated for 48 hr
at 30,C. Blue halos surrounding the discs indicate
03-galactosidase enzyme induction. (B) The three
aromatase inhibitors 40HA, ATD, and AG) were
tested on the same yeast strain under the same
conditions*A r -ib .e in A exct tha
Figdrosen8.dConexpwasso omitteddromgten medium.an
inhibitors (Figure 9). Naringenin wasweakly
positive in the yeast screening method. We
will evaluate the method using other com-
pounds that inhibit aromatase. For a high-
throughput screening, compounds from a
96-well plate can be delivered by a robot
onto a large agar plate that can hold 576
samples. Thus, a large number of com-
pounds can bescreened each day.
The sensitivity ofthis screening assay also
depends on the choice and concentrations of
substrates used because residual substrateswill
lead to high background. We found that
androstenedione is a better substrate than
testosterone and that the optimal concentra-
tion ofandrostenedione used is 20 nM. In
theory, the androgen receptor and the andro-
gen response element can be substituted with
the estrogen receptor and the estrogen
response element for this nonradioactive
screen. In the latter case, an aromatizable
androgen is converted to estrogen, which
binds to the estrogen receptor and subse-
quently induces the reporter enzyme. On a
plate assay, the yeast cells will turn blue as a
resultofreporterenzyme induction. The dear
halo will appear in the presence of an aro-
matase inhibitor. In practice, it is more diffi-
cult to identify activity against a blue back-
ground. Furthermore, the screen using estro-
gen receptor expression does not provide
information on androgenicity of the
inhibitor. In addition, it seems that there are
more estrogenic environmental chemicals
identified than androgenic chemicals. This
will create problems insuchyeastscreening in
that aromatase noninhibitors cannot be
distinguished from estrogen mimics. Thus,
Figure 9. Testing of endocrine disruptors in the
yeastscreening assay. Abbreviations: AG, aminog-
lutethimide; C, chrysin; N, naringenin; a-N, naph-
tholflavone. Three flavones(C, N, and a-N) and the
aromatase inhibitor (AG) were tested in the assay
in the presence of 20 nM androstenedione, under
conditions described in Figure 8. The numbers in
the brackets indicate micrograms of compounds
onthe discs. Blue halos surrounding the discs indi-
cate p-galactosidase enzyme induction.
we have chosen the androgen-responsive tran-
scription unitforthisscreen development.
In summary, wehave reconstituted forthe
first time a yeast transcription unit to study
androgen action and aromatase simultaneous-
ly. This reconstituted system allows us to
develop a high-throughput screening method
without using radioactive substrate to identify
aromatase inhibitors as well as new ligands
(nonaromatizable androgen mimics) for the
androgen receptors. In addition, this screening
method also allows us to distinguish nonan-
drogenic aromatase inhibitors from inhibitors
with androgenic activity. This yeast screening
methodwill be useful to screen environmental
chemicals for their antiaromatase activity and
fortheir interactionwithandrogen receptor.
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